Cardiovascular ramifications of therapy-induced endothelial cell senescence in cancer survivors

Biochim Biophys Acta Mol Basis Dis. 2022 Apr 1;1868(4):166352. doi: 10.1016/j.bbadis.2022.166352. Epub 2022 Jan 15.

Abstract

Cancer survivorship has remarkably improved over the past decades; nevertheless, cancer survivors are burdened with multiple health complications primarily caused by their cancer therapy. Therapy-induced senescence is recognized as a fundamental mechanism contributing to adverse health complications in cancer survivors. In this mini-review, we will discuss the recent literature describing the mechanisms of cancer therapy-induced senescence. We will focus on endothelial cell senescence since it has been shown to be a key player in numerous cardiovascular complications. We will also discuss novel senotherapeutic approaches that have the potential to combat therapy-induced endothelial cell senescence.

Keywords: Anthracyclines; Cancer therapy; Cardio-oncology; Endothelial cells; Radiation; Senescence.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anthracyclines / adverse effects
  • Anthracyclines / pharmacology
  • Anthracyclines / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cardiovascular Diseases / etiology*
  • Cellular Senescence* / drug effects
  • Cellular Senescence* / radiation effects
  • Endothelial Cells / cytology
  • Endothelial Cells / metabolism
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / pathology
  • Neoplasms / radiotherapy
  • Radiation, Ionizing

Substances

  • Anthracyclines
  • Antineoplastic Agents